Literature DB >> 19479389

[Immunosuppression after heart and lung transplantation].

O Wendler1, H J Schäfers.   

Abstract

In the last two decades heart and lung transplantation have evolved to an accepted treatment of endstage heart and lung failure. A differentiated immuno-suppressive regimen is the long term basis of successful transplantation and must be adopted to the individual patient. Rejection and immunosuppression with potential side effects must be balanced to achieve optimal outcome in each patient. In the long-term follow up an efficient diagnosis and treatment of rejection probably also results in reduction of chronic organ failure and improvement of general postoperative results. In cases of vasculopathy after heart transplantation or obliterative bronchiolitis after lung transplantation alternative immunosuppressive drugs are options in the medical therapy. We present our postoperative management protocol after heart and lung transplantation. Potential problems, new immunosuppressive options and side-effects of immunosuppression are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 19479389     DOI: 10.1007/BF03041972

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  14 in total

Review 1.  Cardiac transplantation: recipient selection, donor procurement, and medical follow-up. A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association.

Authors:  J B O'Connell; R C Bourge; M R Costanzo-Nordin; D J Driscoll; J P Morgan; E A Rose; B F Uretsky
Journal:  Circulation       Date:  1992-09       Impact factor: 29.690

Review 2.  In vivo immunosuppressive mechanisms.

Authors:  P F Halloran; L W Miller
Journal:  J Heart Lung Transplant       Date:  1996-10       Impact factor: 10.247

3.  Immunologic consequences of organ transplantation: implications for therapeutic development.

Authors:  L J Thomas; U S Ryan
Journal:  J Heart Lung Transplant       Date:  1995 Sep-Oct       Impact factor: 10.247

4.  The Registry of the International Society for Heart and Lung Transplantation: fourteenth official report--1997.

Authors:  J D Hosenpud; L E Bennett; B M Keck; B Fiol; R J Novick
Journal:  J Heart Lung Transplant       Date:  1997-07       Impact factor: 10.247

5.  Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.

Authors:  M R Costanzo; D M Koch; S G Fisher; A L Heroux; W G Kao; M R Johnson
Journal:  J Heart Lung Transplant       Date:  1997-02       Impact factor: 10.247

6.  Methotrexate for lung transplant recipients with steroid-resistant acute rejection.

Authors:  B C Cahill; M K O'Rourke; K A Strasburg; K Savik; J Jessurun; R M Bolman; M I Hertz
Journal:  J Heart Lung Transplant       Date:  1996-11       Impact factor: 10.247

7.  [Heart transplantation--postoperative management].

Authors:  H J Schäfers; A Haverich; T Wahlers; G Herrmann; K Frimpong-Boateng; H G Fieguth; J Kemnitz; H G Borst
Journal:  Z Kardiol       Date:  1987-05

8.  Cardiac transplantation: the Stanford experience in the cyclosporine era.

Authors:  G E Sarris; K A Moore; J S Schroeder; S A Hunt; M B Fowler; H B Valantine; R H Vagelos; M E Billingham; P E Oyer; E B Stinson
Journal:  J Thorac Cardiovasc Surg       Date:  1994-08       Impact factor: 5.209

9.  A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.

Authors:  T C Merigan; D G Renlund; S Keay; M R Bristow; V Starnes; J B O'Connell; S Resta; D Dunn; P Gamberg; R M Ratkovec
Journal:  N Engl J Med       Date:  1992-04-30       Impact factor: 91.245

Review 10.  Opportunistic infections in the cardiac transplant patient.

Authors:  S J Thaler; R H Rubin
Journal:  Curr Opin Cardiol       Date:  1996-03       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.